PML often has a large premium to NAV - today, it sits at par value. Click here to read why I have initiated a position in the CEF.Read full newsRead More
EMB yields 7.3%, thanks to elevated US Treasury yields and relatively high credit spreads. See why the ETF is likely to outperform inflation in the coming years.Read full newsRead More
Super Micro has largely avoided much of the destruction faced by its semi peers with significant consumer exposure. Read more to see why we rate SMCI a Hold.Read full newsRead More
Sysco is a high-quality company with strong competitive advantages and it has a history of outperforming the market. Read why SYY stock is a weak Buy.Read full newsRead More
Cintas Corporation outperformed not only the market but most other companies. Learn more about my thoughts on CTAS stock and my recommendation.Read full newsRead More
Chimera is under intense pressure from the current macroeconomic environment. Read more to see why the preferreds (CIM.PB) offer a safer way to gain exposure.Read full newsRead More
Progress Software is acquiring on-premise NoSQL database vendor MarkLogic for $355m. Learn more about the deal and my recommendation.Read full newsRead More
Warren Buffett's Berkshire Hathaway bought an over $4 billion stake in TSMC in Q3, 2022. Find out why I rate TSM stock a strong buy.Read full newsRead More
Amazon seems finally ready to enter a formal film strategy centered on the multiplex first-window. This is an important development in becoming a true media conglomerate.Read full newsRead More
We like boring businesses that are essential in all market conditions. Find out 2 dividend-growing picks yielding up to 8% to build your income in this bear market.Read full newsRead More
By yield, ZIM leads the top-ten All-Star-Value field of CTRA, ORCC, PXD, KEN, PBR, ICL, HIMX, AKO.B, LPG, and ZIM. Click here to read more.Read full newsRead More
Alleima (SAMHF) will be debt free and has pledged to pay 50% of its normalized net income as a dividend. Find out why I'm bullish on the stock.Read full newsRead More
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management. Pros and cons to owning his top 5 stocks.Read full newsRead More
Golden Ocean's stellar dividend yield of 13.8% should not be ignored. See why we continue to rate GOGL stock as a Buy.Read full newsRead More
Following a promising rally in October FY22, Inhibrx failed to break to new highs. Read more to see my technical analysis on INBX and my fair value price range.Read full newsRead More
UTG yields 7.92% and pays monthly and its total return outperformed S&P over the past year and most recent trading quarter. See why I rate the fund a buy.Read full newsRead More
EOG Resources success is based on its operational excellence. See why EOG stock represents a compelling investment for long-term focused investors.Read full newsRead More
US equity markets rallied on the first week of the year after employment data showed strong job growth. Learn more about real estate weekly outlook.Read full newsRead More
With underlying business momentum cooling off, MKS Instruments is not out of the woods yet. Click here for a full investment analysis of MKSI stock.Read full newsRead More
Immunovant is developing a similar drug to argenx, but at 10% of argenx's valuation. Read more to see the growth catalysts, risks and why I consider IMVT stock a buy now.Read full newsRead More